These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 25045247)

  • 1. Review of nemonoxacin with special focus on clinical development.
    Qin X; Huang H
    Drug Des Devel Ther; 2014; 8():765-74. PubMed ID: 25045247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated safety summary of phase II and III studies comparing oral nemonoxacin and levofloxacin in community-acquired pneumonia.
    Cheng SL; Wu RG; Chuang YC; Perng WC; Tsao SM; Chang YT; Chang LW; Hsu MC
    J Microbiol Immunol Infect; 2019 Oct; 52(5):743-751. PubMed ID: 30616912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.
    Guo B; Wu X; Zhang Y; Shi Y; Yu J; Cao G; Zhang J
    Clin Drug Investig; 2012 Jul; 32(7):475-86. PubMed ID: 22650326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial.
    Yuan J; Mo B; Ma Z; Lv Y; Cheng SL; Yang Y; Tong Z; Wu R; Sun S; Cao Z; Wu J; Zhu D; Chang L; Zhang Y;
    J Microbiol Immunol Infect; 2019 Feb; 52(1):35-44. PubMed ID: 30181096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia.
    van Rensburg DJ; Perng RP; Mitha IH; Bester AJ; Kasumba J; Wu RG; Ho ML; Chang LW; Chung DT; Chang YT; King CH; Hsu MC
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4098-106. PubMed ID: 20660689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, multicenter Phase II study comparing the efficacy and safety of oral nemonoxacin with oral levofloxacin in the treatment of community-acquired pneumonia.
    Liu Y; Zhang Y; Wu J; Zhu D; Sun S; Zhao L; Wang X; Liu H; Ren Z; Wang C; Xiu Q; Xiao Z; Cao Z; Cui S; Yang H; Liang Y; Chen P; Lv Y; Hu C; Lv X; Liu S; Kuang J; Li J; Wang D; Chang L
    J Microbiol Immunol Infect; 2017 Dec; 50(6):811-820. PubMed ID: 26748734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nemonoxacin (TG-873870) for treatment of community-acquired pneumonia.
    Lai CC; Lee KY; Lin SW; Chen YH; Kuo HY; Hung CC; Hsueh PR
    Expert Rev Anti Infect Ther; 2014 Apr; 12(4):401-17. PubMed ID: 24579813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential role of nemonoxacin for treatment of common infections.
    Huang CH; Lai CC; Chen YH; Hsueh PR
    Expert Opin Pharmacother; 2015 Feb; 16(2):263-70. PubMed ID: 25529577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
    Lin L; Chang LW; Tsai CY; Hsu CH; Chung DT; Aronstein WS; Ajayi F; Kuzmak B; Lyon RA
    Antimicrob Agents Chemother; 2010 Jan; 54(1):405-10. PubMed ID: 19884368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
    Chung DT; Tsai CY; Chen SJ; Chang LW; King CH; Hsu CH; Chiu KM; Tan HC; Chang YT; Hsu MC
    Antimicrob Agents Chemother; 2010 Jan; 54(1):411-7. PubMed ID: 19884374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic Evaluation of Nemonoxacin, Moxifloxacin and Levofloxacin in the Treatment of Early Community-Acquired Pneumonia with Possible Pulmonary Tuberculosis.
    Zhao M; Chi Z; Pan X; Yin Y; Tang W
    Int J Environ Res Public Health; 2022 Apr; 19(8):. PubMed ID: 35457683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, tolerability, and pharmacokinetics of intravenous nemonoxacin in healthy chinese volunteers.
    Cao GY; Zhang J; Zhang YY; Guo BN; Yu JC; Wu XJ; Chen YC; Wu JF; Shi YG
    Antimicrob Agents Chemother; 2014 Oct; 58(10):6116-21. PubMed ID: 25092690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tentative clinical breakpoints and epidemiological cut-off values of nemonoxacin for Streptococcus pneumoniae and Staphylococcus aureus isolates associated with community-acquired pneumonia.
    Jean SS; Chang LW; Hsueh PR
    J Glob Antimicrob Resist; 2020 Dec; 23():388-393. PubMed ID: 33207229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Nemonoxacin vs Levofloxacin in Patients With Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Control Trials.
    Khan AS; Iqbal A; Muhammad AA; Mazhar F; Lodhi MF; Ahmed KF; Kumar S; Varrassi G; Khatri M
    Cureus; 2023 Apr; 15(4):e37650. PubMed ID: 37200652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selected Mutations by Nemonoxacin and Fluoroquinolone Exposure Among Relevant Gram-Positive Bacterial Strains in Taiwan.
    Yang JJ; Cheng A; Tai HM; Chang LW; Hsu MC; Sheng WH
    Microb Drug Resist; 2020 Feb; 26(2):110-117. PubMed ID: 31478786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and Pharmacodynamics of Nemonoxacin in a Neutropenic Murine Lung Infection Model Against
    Li X; Chen Y; Xu X; Li Y; Fan Y; Liu X; Bian X; Wu H; Zhao X; Feng M; Guo B; Zhang J
    Front Pharmacol; 2021; 12():658558. PubMed ID: 34017256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nemonoxacin: first global approval.
    Poole RM
    Drugs; 2014 Aug; 74(12):1445-53. PubMed ID: 25079302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.
    Croom KF; Goa KL
    Drugs; 2003; 63(24):2769-802. PubMed ID: 14664657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicentre, randomised, double-blind, double-dummy, parallel-controlled, phase 3 clinical trial assessing the efficacy and safety of intravenous nemonoxacin malate vs. levofloxacin for community-acquired pneumonia in adult patients.
    Li Y; Zhu D; Sun S; Chang X; Cao Z; Yang Y; Fu X; Li X; Xu J; Zhu Y; Hui F; Xu X; Chen Z; Peng L; Ma Z; Mo B; Li C; Lv Y; Zhao L; Zhu G; He Y; Liu H; Chen J; Wang Y; Liang Y; Lu Y; Qin Z; Yang H; Zhang M; Wu S; Tong Z; Ye F; Xiao Z; Wang X; Qiu C; Kuang J; Huang H; Wang K; Ying K; Jin F; Lv X; Huang Y; Liu D; Wang W; Zhang Y
    Int J Antimicrob Agents; 2024 Jun; 64(2):107235. PubMed ID: 38851462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrative population pharmacokinetic/pharmacodynamic analysis of nemonoxacin capsule in Chinese patients with community-acquired pneumonia.
    Chen Y; Wu X; Tsai C; Chang L; Yu J; Cao G; Guo B; Shi Y; Zhu D; Hu F; Yuan J; Liu Y; Zhao X; Zhang Y; Wu J; Zhang J
    Front Pharmacol; 2023; 14():912962. PubMed ID: 36923351
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.